|

Prevention of NAFLD and CVD Through Lifestyle Intervention

RECRUITINGN/ASponsored by Pontificia Universidad Catolica de Chile
Actively Recruiting
PhaseN/A
SponsorPontificia Universidad Catolica de Chile
Started2021-09-27
Est. completion2025-04-28
Eligibility
Age45 Years – 60 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05618626

Summary

Prevention of non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) through lifestyle intervention (MAUCO+) is a clinical trial that aims to improve sarcopenia, aerobic capacity, body composition, and lipid profile, insulin resistance, cardiovascular risk, NAFLD, and maintain a healthier lifestyle. Through the implementation of physical activity and nutritional programs.

Eligibility

Age: 45 Years – 60 YearsHealthy volunteers accepted
Inclusion Criteria:

* With and without gallstones disease
* With various degrees of NAFLD (none too severe)

Exclusion Criteria:

* Any significant comorbidity or physical limitation to undergo resistance exercise program
* Use of medications that alter muscle mass (e.g., corticosteroids)
* History of hepatitis B or C
* Use of hepatotoxic drugs

Conditions3

Gallstone DiseaseLiver DiseaseNon Alcoholic Fatty Liver Disease

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.